Carter Gould
Stock Analyst at Cantor Fitzgerald
(3.70)
# 765
Out of 5,241 analysts
220
Total ratings
53.49%
Success rate
5.84%
Average return
Main Sectors:
Stocks Rated by Carter Gould
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Overweight | $1,205 → $1,230 | $1,004.92 | +22.40% | 16 | May 1, 2026 | |
| ABBV AbbVie | Reiterates: Overweight | $240 | $210.39 | +14.07% | 20 | Apr 30, 2026 | |
| REGN Regeneron Pharmaceuticals | Reiterates: Overweight | $800 | $698.25 | +14.57% | 23 | Apr 23, 2026 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $45 → $54 | $57.00 | -5.26% | 17 | Apr 8, 2026 | |
| AMGN Amgen | Reiterates: Neutral | $350 | $326.31 | +7.26% | 20 | Apr 8, 2026 | |
| GILD Gilead Sciences | Maintains: Overweight | $135 → $155 | $129.58 | +19.62% | 17 | Feb 11, 2026 | |
| PFE Pfizer | Reiterates: Neutral | $27 | $25.33 | +6.59% | 17 | Feb 4, 2026 | |
| MRK Merck & Co. | Maintains: Neutral | $116 → $120 | $111.38 | +7.74% | 12 | Feb 4, 2026 | |
| NUVL Nuvalent | Maintains: Overweight | $100 → $112 | $102.30 | +9.48% | 2 | Oct 31, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $485 | $436.95 | +11.00% | 4 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | n/a | $52.39 | - | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $160 → $165 | $158.42 | +4.15% | 12 | Dec 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $42.59 | -53.04% | 6 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $190 → $180 | $192.95 | -6.71% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $60 | $14.63 | +310.12% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $3 | $0.68 | +341.44% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $9 | $1.29 | +597.67% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $100 → $95 | $75.85 | +25.25% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $25 → $20 | $6.57 | +204.41% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $14 → $12 | $2.16 | +455.56% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $2 → $1.5 | $0.34 | +341.18% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $392 → $380 | $136.24 | +178.92% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $75 → $82 | $95.31 | -13.96% | 5 | Jan 16, 2019 |
Eli Lilly and Company
May 1, 2026
Maintains: Overweight
Price Target: $1,205 → $1,230
Current: $1,004.92
Upside: +22.40%
AbbVie
Apr 30, 2026
Reiterates: Overweight
Price Target: $240
Current: $210.39
Upside: +14.07%
Regeneron Pharmaceuticals
Apr 23, 2026
Reiterates: Overweight
Price Target: $800
Current: $698.25
Upside: +14.57%
Bristol-Myers Squibb Company
Apr 8, 2026
Maintains: Neutral
Price Target: $45 → $54
Current: $57.00
Upside: -5.26%
Amgen
Apr 8, 2026
Reiterates: Neutral
Price Target: $350
Current: $326.31
Upside: +7.26%
Gilead Sciences
Feb 11, 2026
Maintains: Overweight
Price Target: $135 → $155
Current: $129.58
Upside: +19.62%
Pfizer
Feb 4, 2026
Reiterates: Neutral
Price Target: $27
Current: $25.33
Upside: +6.59%
Merck & Co.
Feb 4, 2026
Maintains: Neutral
Price Target: $116 → $120
Current: $111.38
Upside: +7.74%
Nuvalent
Oct 31, 2025
Maintains: Overweight
Price Target: $100 → $112
Current: $102.30
Upside: +9.48%
Vertex Pharmaceuticals
Aug 5, 2025
Maintains: Overweight
Price Target: $535 → $485
Current: $436.95
Upside: +11.00%
Apr 22, 2025
Initiates: Overweight
Price Target: n/a
Current: $52.39
Upside: -
Dec 23, 2024
Maintains: Overweight
Price Target: $160 → $165
Current: $158.42
Upside: +4.15%
Nov 1, 2024
Maintains: Overweight
Price Target: $18 → $20
Current: $42.59
Upside: -53.04%
Oct 31, 2024
Maintains: Equal-Weight
Price Target: $190 → $180
Current: $192.95
Upside: -6.71%
Aug 14, 2024
Maintains: Overweight
Price Target: $200 → $60
Current: $14.63
Upside: +310.12%
Jun 13, 2024
Maintains: Overweight
Price Target: $7 → $3
Current: $0.68
Upside: +341.44%
Jun 11, 2024
Initiates: Overweight
Price Target: $9
Current: $1.29
Upside: +597.67%
May 23, 2024
Maintains: Overweight
Price Target: $100 → $95
Current: $75.85
Upside: +25.25%
Apr 16, 2024
Maintains: Overweight
Price Target: $25 → $20
Current: $6.57
Upside: +204.41%
May 5, 2023
Maintains: Overweight
Price Target: $14 → $12
Current: $2.16
Upside: +455.56%
Mar 21, 2023
Maintains: Equal-Weight
Price Target: $2 → $1.5
Current: $0.34
Upside: +341.18%
Jan 20, 2022
Maintains: Equal-Weight
Price Target: $392 → $380
Current: $136.24
Upside: +178.92%
Jan 16, 2019
Downgrades: Neutral
Price Target: $75 → $82
Current: $95.31
Upside: -13.96%